Profile

MD, Carol Davila University of Medicine and Pharmacy





GS-US-292-0104 A Phase 3, Double blind study to evaluate the safety and efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Verus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Di
12/01/2012 - 07/31/2015 (PI)
Gilead Sciences, Inc.


GS-US-292-0111 A Phase 3, Double blind study to evaluate the safety and efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Verus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Di
12/01/2012 - 07/31/2015 (PI)
Gilead Sciences, Inc.


A Multicenter, Randomized, Open, Comparative Trial of Maraviroc Versus Etravirine each in Combination with Darrunavir/Ritonavir and Raltegravir for the Treatment of Antiretroviral-Experienced HIV
02/01/2009 - 01/31/2015 (PI)
Pfizer, Inc.



GS-US-366-1216: A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Effi…
06/02/2015 - 05/31/2017 (PI)
Gilead Sciences


Title


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Jarrett OD, Wanke CA, Ruthazer R, Bica I, Isaac R, Knox TA. Metabolic syndrome predicts all-cause mortality in persons with human immunodeficiency virus. AIDS Patient Care STDS. 2013 May; 27(5):266-71. PMID: 23651103; PMCID: PMC3651687; DOI: 10.1089/apc.2012.0402;
     
  2. McGovern BH, Birch C, Zaman MT, Bica I, Stone D, Quirk JR, Davis B, Zachary K, Basgoz N, Graeme-Cook F, Gandhi RT. Managing symptomatic drug-induced liver injury in HIV-hepatitis C virus-coinfected patients: a role for interferon. Clin Infect Dis. 2007 Nov 15; 45(10):1386-92. PMID: 17968840
     
  3. McGovern BH, Wurcel A, Kim AY, Schulze zur Wiesch J, Bica I, Zaman MT, Timm J, Walker BD, Lauer GM. Acute hepatitis C virus infection in incarcerated injection drug users. Clin Infect Dis. 2006 Jun 15; 42(12):1663-70. PMID: 16705568
     
  4. McGovern B, Fiore J, Wurcel A, Taglienti P, Bradley M, Galvin S, Libone G, Ramsey J, Molinaro-Gudas V, Drewniak S, Amick C, Andalkar A, Scheft H, Bica I. Delivering therapy for hepatitis C virus infection to incarcerated HIV-seropositive patients. Clin Infect Dis. 2005 Jul 1; 41 Suppl 1:S56-62. PMID: 16265615
     
  5. Mangili A, Bica I, Snydman DR, Hamer DH. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2005 Apr 1; 40(7):1058-60.View Related Profiles. PMID: 15825002
     
  6. Jacobson DL, Bica I, Knox TA, Wanke C, Tchetgen E, Spiegelman D, Silva M, Gorbach S, Wilson IB. Difficulty swallowing and lack of receipt of highly active antiretroviral therapy predict acute weight loss in human immunodeficiency virus disease. Clin Infect Dis. 2003 Nov 15; 37(10):1349-56. PMID: 14583869
     
  7. McGovern B, Bica I. Should treatment of hepatitis C in HIV-seropositive and HIV-seronegative patients with hemophilia include induction doses of interferon? Clin Infect Dis. 2003 Aug 1; 37(3):463-4; author reply 464-5. PMID: 12884180
     
  8. Bica I, Tang AM, Skinner S, Spiegelman D, Knox T, Gorbach S, Wilson IB. Use of complementary and alternative therapies by patients with human immunodeficiency virus disease in the era of highly active antiretroviral therapy. J Altern Complement Med. 2003 Feb; 9(1):65-76. PMID: 12676036
     
  9. McGovern B, Bica I. Risk of HAART therapy in hepatitis C. Hepatology. 2002 Mar; 35(3):730. PMID: 11870393
     
  10. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, Snydman DR. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001 Feb 1; 32(3):492-7. PMID: 11170959
     
Showing 10 of 11 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.



Contact for Mentoring: